Some cancer patients don't respond to the latest immune-boosting drugs because the tumor finds a way to hide or resist. This project uses a special antibody that acts like a key to unlock that resistance and stop the cancer from spreading. It essentially makes the tumor vulnerable again so the existing immunotherapy can actually work.
Many cancer patients do not respond to Immune Checkpoint Inhibitors (ICIs) due to primary or secondary resistance, leaving a significant care gap and limited treatment options.
A humanized monoclonal antibody (NP137) targeting netrin-1 and a corresponding proof-of-concept clinical trial to test its efficacy in combination with immunotherapy.
If you are a biotech drug developer dealing with low patient response rates to Immune Checkpoint Inhibitors — this project developed NP137 that alleviates resistance to these treatments. This allows for the creation of combination therapies to increase overall survival.
If you are an oncology clinic dealing with patients who are primary refractory to ICIs — this project developed a proof-of-concept clinical trial for NP137 that targets the epithelial-mesenchymal-transition. This provides a new treatment option for patients with limited choices.
If you are a CRO dealing with the need for first-in-class therapeutic antibodies — this project developed a humanized monoclonal antibody targeting netrin-1. It offers a validated mode-of-action published in Nature® for clinical trial execution.
Based on available project data, the specific cost or price of the treatment is not disclosed; however, the project received an EU contribution of EUR 2,500,000.
Based on available project data, the project is currently in the clinical trial phase to assess efficacy, which precedes full industrial scale-up.
Based on available project data, the antibody NP137 was developed by NETRIS Pharma, and its mode-of-action has been published in two Nature® papers in August 2023.
The project period is from 2022-09-01 to 2025-09-30, suggesting results are expected by late 2025.
NP137 is designed to be used on top of immunotherapy to alleviate resistance to Immune Checkpoint Inhibitors (ICIs).
The project is led by a single partner, NETRIS PHARMA SAS, a French SME. This 100% industry-led consortium indicates a strong commercial drive, as the company is managing the entire transition from preclinical success to clinical trials without university partners in the consortium.
Contact NETRIS PHARMA SAS in Lyon, France
Contact us to explore licensing opportunities for NP137
